In the MM field, the utilization of CAR-T cells lies in second generation CAR (with a costimulatory molecule, 4-1bb or CD28) and they principally target B cell maturation antigen (BCMA), which is very specific to the plasma cell (PC), and participate in the differentiation of B cells into PCs and promote their survival. Here, TNFRSF17 is linked to Miyoshi myopathy.